by Truveta Research | Oct 17, 2023 | Research, Research Insights
Social drivers of health (SDOH), such as increased financial struggles and decreased social support, have been shown to be correlated with decreased medication adherence. In this study of patients with type 2 diabetes, we saw an increased rate of medication adherence...
by Truveta Research | Oct 5, 2023 | Research, Research Insights
Annually, over 125,000 deaths are associated with poor medication adherence. The proportion of days covered (PDC) is a common method to measure adherence. When controlling for age, sex, race, and ethnicity, we found similar rates of first year medication adherence for...
by Truveta Research | Jul 10, 2023 | Research, Research Insights
We explored the demographic characteristics of patients with type 2 diabetes mellitus, heart failure, and chronic kidney disease who received a prescription for empagliflozin (Jardiance) and/or dapagliflozin (Farxiga), two commonly used SGLT2i drugs. We saw...
by Truveta Research | Jun 6, 2023 | Research, Research Insights
Beginning in Fall 2022, the news media has reported extensively on the use of Glucagon-like peptide-1 receptor agonist (GLP-1s) for weight loss (Belluz, 2023). Physicians have taken to TikTok to promote GLP-1s for weight loss, and celebrities & influencers – such...
by Truveta Research | May 9, 2023 | Research, Research Insights
This blog is an extension of our poster presented at ISPOR, titled Real-World Effectiveness of SGLT2 Inhibitors Vs Metformin as First-Line Therapy in Type 2 Diabetes. Individuals with type 2 diabetes mellitus (T2DM) have a higher risk of cardiovascular disease...
